Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by...

Preclinical data indicate that SDX-7320 inhibits tumor growth and counteracts treatment-induced metabolic dysfunction, a safety concern that can interrupt PI3K/Akt/mTOR cancer therapy and lead to...(PRWeb October 21, 2020)Read the full story at https://www.prweb.com/releases/clinical_drug_candidate_sdx_7320_offsets_hyperglycemia_caused_by_pi3k_akt_mtor_cancer_therapies_and_restores_insulin_sensitivity_syndevrx_s_preclinical_studies_show/prweb17481606.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news